Skip to content

Study of Postprandial Incretin Response in Women With Gestational Diabetes

Reduced Postprandial GLP-1 Response in Gestational Diabetes Mellitus: a Fully Reversible Phenomenon

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01274052
Enrollment
19
Registered
2011-01-11
Start date
2007-03-31
Completion date
2008-07-31
Last updated
2011-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes Mellitus

Keywords

Gestational diabetes mellitus, Meal test, Incretin hormones, Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic polypeptide, Insulin, C-peptide, Glucagon

Brief summary

The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide and glucagon. The researchers aimed to investigate whether women with gestational diabetes mellitus exhibit decreased postprandial GLP-1 responses, and if so, whether this deficiency ceases following delivery when normal glucose tolerance is reestablished.

Detailed description

The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide and glucagon. The researchers aimed to investigate whether women with gestational diabetes mellitus exhibit decreased postprandial GLP-1 responses, and if so, whether this deficiency ceases following delivery when normal glucose tolerance is reestablished.

Interventions

Liquid meal test

Sponsors

The Danish Diabetes Association
CollaboratorOTHER
Aase and Ejnar Danielsens Foundation
CollaboratorOTHER
The Novo Nordic Foundation
CollaboratorOTHER
University Hospital, Gentofte, Copenhagen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Normal haemoblobin * Willingness to participate

Exclusion criteria

* First degree relative with diabetes * Diabetes before pregnancy * Positive islet cell- and GAD-65 autoantibodies

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026